Percutaneous coronary intervention platelet function testing
|
Percutaneous Coronary Intervention Guidelines Microchapters |
|
PCI Approaches: |
|---|
|
CAD Revascularization: |
|
Pre-procedural Considerations: |
|
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
|
Quality and Performance Considerations: |
|
Percutaneous coronary intervention platelet function testing On the Web |
|
American Roentgen Ray Society Images of Percutaneous coronary intervention platelet function testing |
|
FDA on Percutaneous coronary intervention platelet function testing |
|
CDC on Percutaneous coronary intervention platelet function testing |
|
Percutaneous coronary intervention platelet function testing in the news |
|
Blogs on Percutaneous coronary intervention platelet function testing |
|
Directions to Hospitals Treating Percutaneous Coronary Intervention |
|
Risk calculators and risk factors for Percutaneous coronary intervention platelet function testing |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)[1]
Post-Procedural Platelet Function Testing (DO NOT EDIT)[1]
| Class III (No Benefit) |
| "1. The routine clinical use of platelet function testing to screen patients treated with clopidogrel who are undergoing PCI is not recommended.[2] (Level of Evidence: C)" |
| Class IIb |
| "1. Platelet function testing may be considered in patients at high risk for poor clinical outcomes.[2] (Level of Evidence: C)" |
| "2. In patients treated with clopidogrel with high platelet reactivity, alternative agents, such as prasugrel or ticagrelor, might be considered.[2] (Level of Evidence: C)" |
References
- ↑ 1.0 1.1 Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 2.2 Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM (2010). "ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons". Journal of the American College of Cardiology. 56 (4): 321–41. doi:10.1016/j.jacc.2010.05.013. PMID 20633831. Retrieved 2011-12-16. Unknown parameter
|month=ignored (help)